What side effects are associated with this type of intervention?

Common treatments for lung cancer, such as targeted therapies and chemoradiotherapy, have several known side effects. Targeted therapies can cause skin toxicity, including rashes and pruritus, which significantly impact the quality of life. Chemoradiotherapy often leads to adverse events like pneumonia, pneumonitis, diarrhea, and fatigue. Both treatment types can also result in nausea, vomiting, and other gastrointestinal issues. These side effects vary in severity and can affect patients' daily lives and overall well-being.

What prior FDA approvals exist?

Several FDA-approved treatments for lung cancer include immunotherapy and chemotherapy agents. Pembrolizumab, an anti-PD-1 therapy, has been approved for use in combination with chemotherapy for advanced non-small-cell lung cancer (NSCLC), showing improved overall survival and progression-free survival. Durvalumab, a PD-L1 antibody, is approved for patients with unresectable stage III NSCLC who have not progressed following concurrent platinum-based chemotherapy and radiation therapy, significantly improving progression-free survival and overall survival. These treatments, along with traditional chemotherapy agents like carboplatin and paclitaxel, are integral in current lung cancer management and are often discussed in shared decision-making tools to help patients understand their options.

What other types of research exist?

Promising alternatives to the Conversation Tool for lung cancer patients considering treatment in 2024 include: 1) Digital decision aids incorporating AI to personalize treatment options based on patient-specific data, 2) Virtual reality platforms for immersive education about treatment pathways, 3) Mobile apps with real-time monitoring and feedback to support decision-making, and 4) Telehealth services offering personalized counseling and interactive decision-making support.

← Back to Search

Decision-Making Support Tool for Lung Cancer (iDECIDE Trial)

N/A

Recruiting

Led By Donald R Sullivan, MD, MA, MCR

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Suspected lung cancer

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a conversation tool designed to help lung cancer patients, particularly those who find medical information hard to understand, make better treatment decisions. The tool aims to improve how patients talk with their doctors and understand their options.

Who is the study for?

This trial is for individuals with suspected lung cancer who are fluent in English, have a life expectancy of more than 6 months, and are currently making treatment decisions. It's aimed at those with lower health literacy to help them understand their options. Non-veterans are specifically included to ensure the study's findings apply broadly.

What is being tested?

The trial is testing a conversation tool designed to improve patient-centered outcomes by aiding decision-making in lung cancer treatments. The goal is to determine if this tool helps patients better understand and participate in choosing their treatment path.

What are the potential side effects?

Since the intervention involves education and questionnaires rather than medical or drug treatments, there aren't direct side effects like you'd expect from medication. However, participants may experience stress or anxiety related to discussing their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am suspected to have lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Decision Conflict

Efficacy of a conversation tool on patients' knowledge of lung cancer

Satisfaction with Communication/Confidence in Decision

+1 more

Secondary study objectives

Acceptability

Decision Regret

Depression/Anxiety

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group I (decision aid)Experimental Treatment2 Interventions

Patients review decision aid.

Group II: Group II (standard of care)Active Control2 Interventions

Patients receive standard of care.

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for lung cancer include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy kills rapidly dividing cancer cells but can also affect normal cells, leading to side effects. Targeted therapy blocks specific molecules involved in cancer growth and spread, offering a more precise approach with potentially fewer side effects. Immunotherapy boosts the body's immune system to recognize and destroy cancer cells, providing a novel way to combat the disease. Radiation therapy uses high-energy rays to kill cancer cells or shrink tumors, often used in combination with other treatments. Understanding these mechanisms helps patients make informed decisions about their treatment options, balancing efficacy and potential side effects.

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC.Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.Patient-Centered Outcome Measures in Lung Cancer Trials.